scispace - formally typeset
M

Marc Hafner

Researcher at Genentech

Publications -  79
Citations -  2956

Marc Hafner is an academic researcher from Genentech. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 22, co-authored 66 publications receiving 2109 citations. Previous affiliations of Marc Hafner include Swiss Institute of Bioinformatics & University of Zurich.

Papers
More filters
Journal ArticleDOI

Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs

TL;DR: GR metrics are shown to be superior to conventional metrics for assessing the effects of small molecule drugs in dividing cells and to improve the study of cell signaling and growth using small molecules and biologics and to facilitate the discovery of drug-response biomarkers and the identification of drugs effective against specific patient-derived tumor cells.
Journal ArticleDOI

The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations

Alexandra B Keenan, +107 more
- 29 Nov 2017 - 
TL;DR: The LINCS program focuses on cellular physiology shared among tissues and cell types relevant to an array of diseases, including cancer, heart disease, and neurodegenerative disorders.
Journal ArticleDOI

L1000CDS2: LINCS L1000 characteristic direction signatures search engine

TL;DR: It is demonstrated that processing the L1000 data with the characteristic direction (CD) method significantly improves signal to noise compared with the MODZ method currently used to compute L1000 signatures.
Journal ArticleDOI

Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold

TL;DR: A phenomenological model of the threshold is identified that can predict fractional killing of cells exposed to natural and synthetic agonists alone or in combination with sensitizing drugs such as bortezomib, providing new insight into the control of cell fate by opposing pro‐death and pro‐survival proteins.